GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
09 oct. 2024 16h15 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01 avr. 2024 07h00 HE | Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2023 16h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces New Chief Financial Officer
28 août 2023 07h00 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
14 août 2023 07h00 HE | Genelux Corporation
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
02 août 2023 16h00 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
20 juil. 2023 16h45 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
10 juil. 2023 07h00 HE | Genelux Corporation
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
29 juin 2023 07h00 HE | Genelux Corporation
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces $18 Million Private Placement
12 juin 2023 07h00 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...